Collegium Pharmaceutical, Inc cash flow statement
In fiscal 2025, Collegium Pharmaceutical, Inc's operations generated $329m of cash; it spent $1.7m on capital projects, leaving free cash flow of $328m. It returned $25.1m through buybacks.
Cash flow statement
| Fiscal year | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −75 | −67 | 169 | 28 | 94 | 104 | 124 | 275 | 205 | 329 | 330 |
| Depreciation and amortisation | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 4 | 4 | 4 |
| Stock-based pay | 6 | 8 | 14 | 17 | 22 | 24 | 23 | 27 | 32 | 42 | 45 |
| Capital spending | 0 | 1 | 5 | 6 | 6 | 2 | 2 | 0 | 2 | 2 | 2 |
| Free cash flow | −76 | −68 | 164 | 21 | 88 | 102 | 123 | 274 | 203 | 328 | 328 |
| Free cash flow after stock pay | −81 | −76 | 150 | 5 | 66 | 77 | 100 | 247 | 171 | 286 | 283 |
| Share buybacks | — | — | — | — | — | 48 | 14 | 75 | 60 | 25 | — |
| Shares issued | 137 | 34 | −0 | — | — | — | — | — | — | — | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −9 | 85 | 55 | 72 | 78 | 123 | 57 | 71 |
| Depreciation and amortisation | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 2 |
| Stock-based pay | 7 | 8 | 12 | 11 | 10 | 10 | 11 | 14 |
| Capital spending | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
| Free cash flow | −9 | 84 | 55 | 72 | 78 | 122 | 57 | 71 |
| Free cash flow after stock pay | −17 | 76 | 43 | 62 | 68 | 113 | 46 | 56 |
Compare with peers
- Corcept Therapeutics Inc cash flow
- Supernus Pharmaceuticals, Inc. cash flow
- Axsome Therapeutics, Inc. cash flow
- Pacira Biosciences, Inc. cash flow
- Amphastar Pharmaceuticals, Inc. cash flow
Head to head: COLL vs CORTCOLL vs SUPNAXSM vs COLL
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies